Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Limited treatment options are available for stage IIIB/IV non‐small cell lung cancer (NSCLC). Nivolumab, a programmed cell death‐1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. The present study investigated the effectiveness and safety of nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Hida, Toyoaki, Nishio, Makoto, Nogami, Naoyuki, Ohe, Yuichiro, Nokihara, Hiroshi, Sakai, Hiroshi, Satouchi, Miyako, Nakagawa, Kazuhiko, Takenoyama, Mitsuhiro, Isobe, Hiroshi, Fujita, Shiro, Tanaka, Hiroshi, Minato, Koichi, Takahashi, Toshiaki, Maemondo, Makoto, Takeda, Koji, Saka, Hideo, Goto, Koichi, Atagi, Shinji, Hirashima, Tomonori, Sumiyoshi, Naoki, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448646/
https://www.ncbi.nlm.nih.gov/pubmed/28266091
http://dx.doi.org/10.1111/cas.13225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448646/
https://www.ncbi.nlm.nih.gov/pubmed/28266091
http://dx.doi.org/10.1111/cas.13225

Ejemplares similares